back to top
Sign in
Join
All News
Clinical Trials
FDA Approvals
Healthcare
More
Drug Discovery
Financial
Manufacturing
Marketing
Uncategorized
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Create an account
Sign up
Welcome!
Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
Search
Sign in / Join
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
A password will be e-mailed to you.
DosEdge: Quick. Clear. Cutting-Edge.
All News
Clinical Trials
FDA Approvals
Healthcare
More
Drug Discovery
Financial
Manufacturing
Marketing
Uncategorized
Uncategorized
All News
Clinical Trials
Drug Delivery
FDA Approvals
Financial
Healthcare
Uncategorized
Roche’s Tecentriq Halves Recurrence, Death Risk in Stage 3 dMMR Colon Cancer
The Roche Tecentriq colon cancer Phase 3 trial reveals a striking 50% decrease in recurrence and mortality among stage 3 dMMR patients when added to chemotherapy—potentially reshaping adjuvant treatment protocols.
No posts to display
